TLBAX Performance — Nuveen Life Balanced Fund
Data updated: 2026-08-27
TLBAX returned +5.37% year to date and +11.90% over one year to Jun 2026. Annualised returns are +11.29% over 3 years and +5.35% over 5 years. The fund trailed its US Multi-Cap Blend category average: $100 invested three years ago grew to $138, against $143 for the category, and to $112 over one year, against $116. Volatility over the past three years was 8.22% a year. In the 12 months to Jun 2026 the fund lost a net $1.4M, and assets reached $69.21M.
TLBAX Growth of $100
What $100 invested in Nuveen Life Balanced Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Multi-Cap Blend category average over the same months.
| Period | TLBAX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $112 | $116 |
| 3 years (Jul 2023 – Jun 2026) | $138 | $143 |
| 5 years (Jul 2021 – Jun 2026) | $130 | $136 |
| Since data start (Jul 2019 – Jun 2026) | $167 | $173 |
TLBAX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +5.37% |
| 1 year | +11.90% |
| 3 years (annualised) | +11.29% |
| 5 years (annualised) | +5.35% |
TLBAX Annual Returns
Calendar-year total returns of Nuveen Life Balanced Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +5.37% |
| 2025 | +12.12% |
| 2024 | +10.38% |
| 2023 | +15.77% |
| 2022 | −16.59% |
| 2021 | +9.78% |
| 2020 | +14.16% |
| 2019 (Jul–Dec) | +5.67% |
TLBAX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.4% | +0.9% | −3.9% | +4.9% | +1.9% | +0.3% | — | — | — | — | — | — |
| 2025 | +2.0% | +0.6% | −2.7% | −0.2% | +2.8% | +3.1% | +0.5% | +1.4% | +2.0% | +1.4% | +0.6% | +0.1% |
| 2024 | +0.7% | +2.0% | +2.3% | −3.3% | +3.1% | +1.6% | +2.0% | +1.8% | +1.2% | −1.9% | +3.0% | −2.4% |
| 2023 | +5.5% | −2.2% | +2.3% | +1.1% | −0.5% | +3.2% | +1.7% | −1.5% | −3.5% | −2.0% | +6.6% | +4.6% |
| 2022 | −4.0% | −2.4% | −0.2% | −6.1% | +0.1% | −5.5% | +5.5% | −3.3% | −6.9% | +3.4% | +5.2% | −2.7% |
| 2021 | −0.6% | +1.4% | +0.9% | +2.8% | +0.9% | +1.0% | +1.0% | +1.1% | −2.5% | +2.7% | −1.5% | +2.1% |
| 2020 | +0.4% | −3.3% | −9.3% | +7.2% | +3.7% | +2.1% | +3.6% | +3.3% | −1.7% | −1.2% | +7.1% | +2.7% |
| 2019 | — | — | — | — | — | — | +0.5% | +0.3% | +0.4% | +1.3% | +1.4% | +1.5% |
TLBAX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 8.22%
- 3-year Sharpe ratio: 0.83 (vs 4.5% risk-free rate)
- Best month: +6.56% (Nov 2023)
- Worst month: −3.87% (Mar 2026)
TLBAX Fund Flows
Monthly money in and out of Nuveen Life Balanced Fund, from SEC Form N-PORT.
- 12-month net flow: −$1.4M
- 12-month gross sales (incl. reinvestments): $5.3M
- Sales ÷ redemptions: 0.79×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $22K | $1.0M | −$994K |
| May 2026 | $14K | $151K | −$137K |
| Apr 2026 | $36K | $47K | −$11K |
| Mar 2026 | $42K | $2.6M | −$2.5M |
| Feb 2026 | $42K | $733K | −$691K |
| Jan 2026 | $25K | $120K | −$95K |
| Dec 2025 | $125K | $97K | $28K |
| Nov 2025 | $77K | $101K | −$24K |
| Oct 2025 | $63K | $689K | −$626K |
| Sep 2025 | $4.8M | $171K | $4.6M |
| Aug 2025 | $51K | $304K | −$253K |
| Jul 2025 | $34K | $743K | −$710K |
TLBAX Assets Under Management
Net assets of Nuveen Life Balanced Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $69.21M |
| 2026-03-31 | $65.66M |
| 2025-12-31 | $70.11M |
| 2025-09-30 | $69.26M |
| 2025-06-30 | $67.09M |
| 2025-03-31 | $64.05M |
| 2024-12-31 | $64.35M |
| 2024-09-30 | $66.85M |
| 2024-06-30 | $66.71M |
| 2024-03-31 | $67.60M |
| 2023-12-31 | $67.88M |
| 2023-09-30 | $62.32M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.